VIRGINIA COMMONWEALTH UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1838-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.vcu.edu
Clinical Trials
615
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (518 trials with phase data)• Click on a phase to view related trials
A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment w/Doppler
- Conditions
- Anterior Cerebral Artery SyndromeAcute Ischemic StrokeCardioembolic StrokeCongestive Heart FailureDiabetesAnterior Cerebral Artery StrokeCoronary Artery DiseaseVasogenic Cerebral Edema
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 100
- Registration Number
- NCT07013396
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
FearLess in NeuroOncology
- Conditions
- Primary Malignant Brain TumorGlioblastoma (GBM)AstrocytomaOligodendrogliomaCaregiver
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 112
- Registration Number
- NCT06989086
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
- Conditions
- Opioid Use DisorderOpioid UseInsomniaOrexin Antagonist
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 100
- Registration Number
- NCT06981195
- Locations
- 🇺🇸
VCU Institute for Drug and Alcohol Studies, Richmond, Virginia, United States
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 33
- Registration Number
- NCT06966388
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders
- Conditions
- Eating Disorder Not Otherwise Specified
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 160
- Registration Number
- NCT06861608
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 123
- Next
News
XPro™ Shows Promise in Reducing Alzheimer's Pathology Following Traumatic Brain Injury in Preclinical Study
INmune Bio's XPro™ (XPro1595, pegipanermin) significantly reduced amyloid formation and improved brain function in transgenic mice following traumatic brain injury.
Ruxolitinib Shows Promise in Treating CAR T-Cell Therapy-Induced Parkinsonism in Multiple Myeloma
Researchers report successful treatment of ciltacabtagene autoleucel-induced parkinsonism in multiple myeloma patients using the JAK inhibitor ruxolitinib, offering a potential solution for this serious complication.
Wegovy Shows Promise in Treating MASH, a Serious Liver Disease
A landmark Phase 3 clinical trial led by VCU and King's College London researchers found semaglutide significantly reduces liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Galmed's Aramchol Shows Promising Results in Enhancing Regorafenib's Efficacy Against GI Cancers
Aramchol, Galmed Pharmaceuticals' SCD1 inhibitor, significantly enhanced the anti-tumor effects of Bayer's Regorafenib in liver and colorectal cancer models through increased autophagy and death receptor signaling.
Dual-Agonist Drug Survodutide Shows Promise in Phase 2 Trial for Fatty Liver Disease Treatment
A Phase 2 clinical trial of survodutide, a dual GLP-1 and glucagon agonist, demonstrated that up to 83% of patients with fatty liver disease showed measurable improvement after 48 weeks of treatment.